LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Search

Incyte Corp

Открыт

СекторЗдравоохранение

105.27 0.54

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

104.56

Макс.

110.19

Ключевые показатели

By Trading Economics

Доход

4.1M

303M

Продажи

-234M

1.3B

P/E

Средняя по отрасли

14.215

49.052

Прибыль на акцию

1.81

Рентабельность продаж

23.834

Сотрудники

2,844

EBITDA

-47M

368M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+4.73% upside

Дивиденды

By Acuity

Следующий отчет о доходах

28 июл. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

1.1B

20B

Предыдущая цена открытия

104.73

Предыдущая цена закрытия

105.27

Новостные настроения

By Acuity

32%

68%

81 / 344 Рейтинг в Healthcare

Incyte Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

10 июн. 2026 г., 21:02 UTC

News

Incyte shares rise in after-market trading on Guggenheim target increase.

9 июн. 2026 г., 20:02 UTC

News

Incyte Corp gains as HC Wainwright raises price target to $140 and the company announces a $1.25 billion acquisition of Vega Therapeutics.

8 июн. 2026 г., 19:42 UTC

Event
Social Media
News

Incyte Corp shares are lower after announcing a $1.25 billion acquisition of Vega Therapeutics, which will impact upcoming financial results significantly.

5 июн. 2026 г., 22:51 UTC

Incyte Corp shares are higher in after-market trading, reflecting positive market sentiment following stronger-than-expected U.S. job growth data.

4 июн. 2026 г., 20:01 UTC

News
Event

Incyte shares rise as results from the Phase 2 PROGRESS study will be presented at ENDO 2026, supporting the FDA's Priority Review of its application.

3 июн. 2026 г., 20:02 UTC

Incyte Corp shares are higher today, breaking a recent trend. The ADP Employment Report showed stronger-than-expected job growth, influencing broader market sentiment.

2 июн. 2026 г., 23:06 UTC

Incyte Corp. shares are trading roughly flat in after-market hours, following a session that saw a peak gain earlier.

1 июн. 2026 г., 19:36 UTC

Social Media
Event
News

Incyte Corp's stock is lower after the Phase 3 frontMIND trial results raised safety concerns despite showing efficacy in treating high-risk lymphoma patients.

29 мая 2026 г., 23:46 UTC

Incyte Corp shares are lower in after-market hours, reflecting a slight decline since Friday's close without any specific news to explain the movement.

28 мая 2026 г., 20:06 UTC

Incyte Corp shares are higher today, recovering from earlier losses amid modest overall market performance. No specific company news was identified to explain the movement.

27 мая 2026 г., 23:06 UTC

Incyte Corp. shares remain roughly flat in after-market trading, with no specific news identified and movement within a narrow range since Wednesday's close.

26 мая 2026 г., 20:06 UTC

Incyte Corp. shares are lower today, reflecting a decline since Friday's close amid broader market focus on upcoming economic data releases.

21 мая 2026 г., 19:26 UTC

News

HC Wainwright & Co. reiterated a Buy rating on Incyte Corp with a $135 price target, contributing to the stock's upward movement since Wednesday.

20 мая 2026 г., 23:56 UTC

Incyte Corp shares are lower in after-market trading, amid tightening global financial conditions and rising policy rates. The broader market has shown recent strength.

19 мая 2026 г., 19:36 UTC

News

Incyte Corp partners with Edison Scientific to use AI in drug discovery. Shares are trading higher, reflecting broader gains in the Biotechnology sector.

18 мая 2026 г., 19:17 UTC

Social Media

Incyte Corp shares decline amid rising Treasury yields and broader market pressures. The stock has finished lower for five consecutive sessions.

15 мая 2026 г., 23:02 UTC

Incyte Corp shares are higher in after-market trading, reversing four consecutive daily declines. No specific news was identified to explain the price movement.

14 мая 2026 г., 20:06 UTC

Incyte Corp shares are lower today amid a downturn in the Biotechnology sub-sector and a broader market decline over three consecutive sessions.

13 мая 2026 г., 20:13 UTC

Incyte Corp shares are lower in after-market trading, continuing a downward trend since Wednesday. No specific company news was identified to explain the movement.

12 мая 2026 г., 19:11 UTC

News
Macro Event

Incyte Corp shares decline despite positive news on EHA Congress. Director Baker Bros. Advisors exercised options for 30,000 shares at $84.53.

11 мая 2026 г., 22:51 UTC

Incyte Corp shares have declined in after-hours trading. This drop coincides with cautious market sentiment ahead of inflation reports, despite trading above its 20-day moving average.

8 мая 2026 г., 19:16 UTC

Event

Incyte Corp shares rise as final data from TRuE-AD4 study released. The study evaluated Opzelura® cream's efficacy for moderate atopic dermatitis.

7 мая 2026 г., 20:15 UTC

Incyte Corp holds steady in after-hours trading. The stock remains above its 20-day moving average, indicating strong performance.

6 мая 2026 г., 19:36 UTC

Correlated Moves

Incyte Corp trades higher, reflecting broader market optimism. Strong U.S. job growth supports bullish sentiment, aligning with recent positive trends in equity markets.

5 мая 2026 г., 23:01 UTC

Incyte Corp's shares declined in after-hours trading. No specific company news has been identified to explain this downturn.

4 мая 2026 г., 19:46 UTC

Correlated Moves
Event
News
Social Media

Incyte gains FDA approval for Jakafi XR, enhancing treatment options. Shares remain stable amid broader market conditions despite this positive news.

1 мая 2026 г., 23:06 UTC

News

Incyte Corp gains FDA approval for Jakafi XR today. The new formulation enhances treatment options for myelofibrosis and GVHD, boosting shares in after-hours trading.

30 апр. 2026 г., 19:51 UTC

Incyte Corp trades lower, falling below its 20-day moving average. This decline contrasts with three consecutive sessions of gains, with no specific news identified.

Сравнение c конкурентами

Изменение цены

Incyte Corp Прогноз

Целевая цена

By TipRanks

4.73% рост

Прогноз на 12 месяцев

Средняя 110.38 USD  4.73%

Максимум 140 USD

Минимум 75 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Incyte Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

19 ratings

8

Покупка

10

Удержание

1

Продажа

Настроения

By Acuity

81 / 344Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat